

**IN THE CLAIMS:**

1. (Previously presented) A solid dosage form comprising:
  - (a) a core comprising an acid-sensitive pharmaceutically active ingredient, an acid-sensitive excipient, or both;
  - (b) a subcoating upon the core comprising a substance having an amino group that reacts with acidic functional groups; and
  - (c) an acidic functional group-containing enteric coating over the subcoating.
2. (Cancelled)
3. (Cancelled)
4. (Original) The solid dosage form of claim 1, wherein the substance that reacts with acidic functional groups comprises an  $\alpha$ -amino acid.
5. (Original) The solid dosage form of claim 1, wherein the substance that reacts with acidic functional groups is selected from glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, lysine, histadine, phenylalanine, tyrosine, tryptophan, and proline.

6. (Original) The solid dosage form of claim 1, wherein the substance that reacts with acidic functional groups comprises about 0.1 to about 12 percent of the dosage form weight.

7. (Original) The solid dosage form of claim 1, wherein the substance that reacts with acidic functional groups comprises about 0.5 to about 9 percent of the dosage form weight.

8. (Original) The solid dosage form of claim 1, wherein the substance that reacts with acidic functional groups comprises about 0.7 to about 7 percent of the dosage form weight.

9. (Currently amended) The solid dosage form of claim ~~2~~ 21, wherein the acid sensitive pharmaceutically active ingredient comprises an antihistamine, an anti-infective, an adrenergic antagonist, or a xanthine.

10. (Currently amended) The solid dosage form of claim ~~2~~ 21, wherein the acid-sensitive pharmaceutically active ingredient comprises an antidepressant.

11. (Currently amended) The solid dosage form of claim ~~2~~ 21, wherein the acid-sensitive pharmaceutically active ingredient comprises a benzimidazole proton pump inhibitor.

12. (Original) A solid dosage form comprising:

(a) a core comprising an acid-sensitive pharmaceutically active ingredient having an amino group;

(b) a subcoating upon the core comprising an  $\alpha$ -amino acid; and

(c) an acidic functional group-containing component in an enteric coating over the subcoating.

13. (Original) The solid dosage form of claim 12, wherein the substance that reacts with acidic functional groups is selected from glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, lysine, histadine, phenylalanine, tyrosine, tryptophan, and proline.

14. (Original) The solid dosage form of claim 12, wherein a reaction product of the  $\alpha$ -amino acid with the acidic functional group-containing component is water-soluble.

15. (Original) The solid dosage form of claim 12, wherein the amino acid comprises about 0.1 to about 12 percent of the dosage form weight.

16. (Original) The solid dosage form of claim 12, wherein the amino acid comprises about 0.5 to about 9 percent of the dosage form weight.

17. (Original) The solid dosage form of claim 12, wherein the amino acid comprises about 0.7 to about 7 percent of the dosage form weight.

18. (Original) A solid dosage form comprising:

(a) a core comprising an acid-sensitive pharmaceutically active ingredient having an amino group;

(b) a subcoating upon the core comprising glycine; and

(c) an enteric coating, comprising an acidic functional group-containing component, over the subcoating.

19. (Original) The solid dosage form of claim 18, wherein the acid-sensitive pharmaceutically active ingredient comprises an antidepressant.

20. (Original) The solid dosage form of claim 18, wherein the acid-sensitive pharmaceutically active ingredient comprises a benzimidazole proton pump inhibitor.

21. (New) The solid dosage form of claim 1, wherein the pharmaceutically active ingredient has an amino group.